Nautilus Biotechnology (NAUT) investor relations material

Executive summary

• Strategic realignment shifts majority of R&D resources to proteoform applications, accelerating assay development and commercial readiness in response to strong customer demand and technical progress.

• Achieved first revenue in Q2 2026, primarily from grant-funded development and early access services, with commercial organization expansion and growing customer engagement.

• Focused on developing the Voyager platform for proteomics, with phased commercialization beginning through Early Access and plans for commercial launch in 2027.

• No material product revenue to date; platform remains in development and subject to technical and market risks.

• Significant investments continue in R&D, commercialization infrastructure, and intellectual property.

Financial highlights

• Q2 2026 revenue was $0.2 million, mainly from grants and early access services; no product sales yet.

• Operating expenses for Q2 2026 were $15.9 million, down 7% year-over-year, driven by lower R&D and SG&A costs.

• Net loss for Q2 2026 was $14.5 million ($0.11 per share), improved from $15 million ($0.12 per share) in the prior year.

• Cash, cash equivalents, and investments totaled $129.2 million as of June 30, 2026, supporting operations into Q1 2028.

• Accumulated deficit reached $361.2 million as of June 30, 2026.

Outlook and guidance

• Full-year 2026 revenue guidance maintained at $0.5 million.

• Voyager Platform pre-orders expected in early 2027, with shipments and consumable kit launches mid-2027.

• Operating expenses expected below prior guidance, with less than 10% year-over-year growth.

• Additional capital will be required to support long-term growth and commercialization, with fundraising anticipated before mid-2027.

• Expenses and losses expected to increase as commercialization and R&D ramp up.